ViiV's injectable Cabenuva beats daily pills in people with detectable HIV in Phase 3b CROWN

ViiV Healthcare, the HIV company majority owned by GSK with Shionogi as a shareholder, said on 6 October 2026 that its phase IIIb CROWN study had met its primary endpoint. At six months, long-acting Cabenuva (cabotegravir plus rilpivirine) suppressed the virus in more people than standard daily oral antiretroviral therapy, in adults and adolescents who entered the study with detectable HIV-1 ¹.

What the trial found

CROWN was an international, randomised, open-label trial. It enrolled approximately 326 adults and adolescents at 85 sites in eight countries ¹. Every participant had taken daily oral treatment before but still had detectable virus, and none had evidence of resistance to integrase inhibitors or to non-nucleoside reverse transcriptase inhibitors, the two drug classes in the regimen ¹. Participants in the long-acting arm started the injectable regimen directly, given six times a year, rather than first being brought to suppression on tablets ¹.

GSK describes the outcome as superior rates of viral suppression against oral standard of care at six months ¹. The announcement does not give the suppression rates in either arm, the size of the difference or any safety data. GSK says full results will be presented at an upcoming scientific meeting ¹.

The trial follows LATITUDE, in which the same regimen beat daily oral therapy at keeping the virus suppressed in people who had reached suppression on tablets but had a history of adherence problems ¹. CROWN tests the step LATITUDE left open: whether people who are not suppressed can move straight onto injections ¹. Jean van Wyk, ViiV's chief medical officer, said the study "was designed to address this important evidence gap" ¹.

What it means for the market

The current licence is narrow. Cabenuva in the US, and Vocabria with Rekambys in the EU and Japan, are approved only for people already virologically suppressed on a stable regimen with no history of treatment failure and no known or suspected resistance to either drug ¹. Use in people with detectable virus is investigational and has no regulatory approval anywhere ¹.

ViiV says the CROWN data will go to health authorities for regulatory review ¹. If regulators accept them, the regimen could be offered to a group that the label now excludes: treatment-experienced patients who are not suppressed on tablets, often because daily dosing has not worked for them. For GSK, that would widen the addressable population for its long-acting HIV franchise. For payers and HIV services, the question would shift from whether to switch stable patients to injections to whether to start harder-to-treat patients on them, with clinic visits six times a year in place of daily pills ¹.

Rilpivirine is a Johnson & Johnson drug, so any label change involves a regimen built from two companies' molecules ¹. The release gives no timetable for filings in the US, EU or UK, and no figures on pricing or expected uptake.

Caveats

The evidence so far is a company announcement of a primary endpoint, without the underlying numbers. The study was open label, and its readout is at six months, so it says nothing yet about longer-term durability ¹. It excluded anyone with resistance to either drug class, which limits how far the result can be applied ¹. Until the full data are presented at a scientific meeting, the size of the benefit, and how it compares with the LATITUDE result, cannot be judged ¹.